One meta-analysis performed by Botticelli and Coll, which focused on anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapies, showed no significant benefit with immunotherapies regarding OS or progression-free survival (PFS) in males vs. females, including those with lung cancer; however, this study did not account for heterogeneity between trials. The gene discussed is CD274; the disease is lung carcinoma.